US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US3662333A
(en)
|
1970-09-08 |
1972-05-09 |
Bendix Corp |
Hydraulic accumulator charge detector and indicating system
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
JPS62129297A
(ja)
|
1985-08-09 |
1987-06-11 |
Toyo Jozo Co Ltd |
カルシトニン遺伝子関連ペプチド誘導体
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1990007936A1
(en)
|
1989-01-23 |
1990-07-26 |
Chiron Corporation |
Recombinant therapies for infection and hyperproliferative disorders
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
EP0465529B1
(en)
|
1989-03-21 |
1998-04-29 |
Vical, Inc. |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
AU641673B2
(en)
|
1989-06-29 |
1993-09-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
WO1991000737A1
(en)
|
1989-07-10 |
1991-01-24 |
Amylin Corporation |
Treatment of obesity and essential hypertension and related disorders
|
EP0845537A1
(en)
|
1989-08-18 |
1998-06-03 |
Chiron Corporation |
Recombinant retroviruses delivering vector constructs to target cells
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
NZ237464A
(en)
|
1990-03-21 |
1995-02-24 |
Depotech Corp |
Liposomes with at least two separate chambers encapsulating two separate biologically active substances
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
JP3534749B2
(ja)
|
1991-08-20 |
2004-06-07 |
アメリカ合衆国 |
アデノウイルスが介在する胃腸管への遺伝子の輸送
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
AU3144193A
(en)
|
1991-11-21 |
1993-06-15 |
Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
CA2137361A1
(en)
|
1992-06-10 |
1993-12-23 |
W. French Anderson |
Vector particles resistant to inactivation by human serum
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
AU668423B2
(en)
|
1992-08-17 |
1996-05-02 |
Genentech Inc. |
Bispecific immunoadhesins
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
AU680459B2
(en)
|
1992-12-03 |
1997-07-31 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
AU6524794A
(en)
|
1993-03-24 |
1994-10-11 |
Amylin Pharmaceuticals, Inc. |
Cloned receptors and methods for screening
|
WO1994023697A1
(en)
|
1993-04-22 |
1994-10-27 |
Depotech Corporation |
Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
CA2166118C
(en)
|
1993-06-24 |
2007-04-17 |
Frank L. Graham |
Adenovirus vectors for gene therapy
|
GB9316989D0
(en)
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
DE69433461T2
(de)
|
1993-09-15 |
2004-11-18 |
Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville |
Rekombinanter Alphavirus Vektor
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
WO1995011984A2
(en)
|
1993-10-25 |
1995-05-04 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
PL314485A1
(en)
|
1993-11-16 |
1996-09-16 |
Depotech Corp |
Bubbles with controllable release of active substances
|
JPH07196700A
(ja)
|
1994-01-06 |
1995-08-01 |
Sando Yakuhin Kk |
抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
|
US6436908B1
(en)
|
1995-05-30 |
2002-08-20 |
Duke University |
Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
|
ES2297831T3
(es)
|
1994-05-09 |
2008-05-01 |
Oxford Biomedica (Uk) Limited |
Vectores retroviricos que presentan una tasa de recombinacion reducida.
|
AU7953194A
(en)
|
1994-08-16 |
1996-03-07 |
Human Genome Sciences, Inc. |
Calcitonin receptor
|
AU4594996A
(en)
|
1994-11-30 |
1996-06-19 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
FR2732220B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
|
FR2732222B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
|
FR2732221B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
|
EP0737471A3
(fr)
|
1995-04-10 |
2000-12-06 |
L'oreal |
Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
|
FR2732598B1
(fr)
|
1995-04-10 |
1997-05-09 |
Oreal |
Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
JPH11512396A
(ja)
|
1995-09-05 |
1999-10-26 |
スミスクライン・ビーチャム・コーポレイション |
化合物および方法
|
AU2731797A
(en)
|
1996-04-15 |
1997-11-19 |
University Of Miami |
Molecular clone of cgrp receptor component protein and uses thereof
|
ATE424463T1
(de)
|
1996-05-06 |
2009-03-15 |
Oxford Biomedica Ltd |
Rekombinationsunfähige retrovirale vektoren
|
US5746694A
(en)
|
1996-05-16 |
1998-05-05 |
Wilk; Peter J. |
Endoscope biopsy channel liner and associated method
|
AU6596096A
(en)
|
1996-07-23 |
1998-02-10 |
Smithkline Beecham Corporation |
Calcitonin gene-related peptide receptor component factor (houdc44)
|
US6586458B1
(en)
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
AU4261697A
(en)
|
1996-09-09 |
1998-03-26 |
Smithkline Beecham Corporation |
Compounds and methods
|
ID21045A
(id)
|
1996-09-10 |
1999-04-08 |
Thomae Gmbh Dr K |
Asam amino termodifikasi, obat-obatan yang mengandung senyawa ini dan proses pembuatannya
|
WO1998056779A1
(en)
|
1997-06-13 |
1998-12-17 |
Smithkline Beecham Corporation |
4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
|
US20030069231A1
(en)
|
1999-10-12 |
2003-04-10 |
Klaus Rudolf |
Modified aminoacids, pharmaceuticals containing these compounds and method for their production
|
WO1999018792A1
(en)
|
1997-10-10 |
1999-04-22 |
Johns Hopkins University |
Gene delivery compositions and methods
|
SE9704770D0
(sv)
|
1997-12-19 |
1997-12-19 |
Astra Ab |
New use
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
GB9809839D0
(en)
|
1998-05-09 |
1998-07-08 |
Glaxo Group Ltd |
Antibody
|
US6552043B1
(en)
|
1998-09-30 |
2003-04-22 |
Merck Sharpe & Dohme Ltd. |
Benzimidazolinyl piperidines as CGRP ligands
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP1031350A1
(en)
|
1999-02-23 |
2000-08-30 |
Warner-Lambert Company |
Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
|
US6313097B1
(en)
|
1999-03-02 |
2001-11-06 |
Boehringer Ingelheim Pharma Kg |
Antagonists of calcitonin gene-related peptide
|
AU3734900A
(en)
|
1999-03-09 |
2000-09-28 |
University Of Southern California |
Method of promoting myocyte proliferation and myocardial tissue repair
|
US6521609B1
(en)
|
1999-08-10 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
US20020162125A1
(en)
|
2001-03-06 |
2002-10-31 |
Anne-Marie Salmon |
Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
|
ATE453661T1
(de)
|
2001-09-27 |
2010-01-15 |
Merck & Co Inc |
Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
|
US6767056B2
(en)
|
2002-01-14 |
2004-07-27 |
Shin Yeh Enterprise Co., Ltd. |
Settee with a foldable tray-support unit
|
DK1527100T3
(da)
|
2002-03-29 |
2009-09-07 |
Schering Corp |
Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
|
US7879991B2
(en)
|
2002-05-06 |
2011-02-01 |
Noxxon Pharma Ag |
CGRP binding nucleic acids
|
US20040110170A1
(en)
|
2002-05-18 |
2004-06-10 |
The Regents Of The University Of California |
Cloning and characterization of calcitonin gene related peptide receptors
|
US7345065B2
(en)
|
2002-05-21 |
2008-03-18 |
Allergan, Inc. |
Methods and compositions for alleviating pain
|
US7097467B2
(en)
|
2002-06-03 |
2006-08-29 |
Wan-Tien Chen |
Dustproof plate fixture for an electrical connector
|
KR20120004541A
(ko)
|
2002-06-05 |
2012-01-12 |
브리스톨-마이어스 스큅 컴퍼니 |
칼시토닌 유전자 관련 펩티드 수용체 길항제
|
ES2263984T3
(es)
|
2002-06-28 |
2006-12-16 |
Domantis Limited |
Ligandos doble-especificos con una vida media serica aumentada.
|
RS52750B
(sr)
|
2002-08-12 |
2013-08-30 |
Birkir Sveinsson |
Upotreba cgrp antagonista za lečenje psorijaze
|
PT1556083E
(pt)
*
|
2002-10-08 |
2011-03-17 |
Rinat Neuroscience Corp |
Métodos para tratar a dor pós-cirúrgica pela administração de um anticorpo contra o factor de crescimento nervoso e composições que contêm o mesmo
|
MXPA05005921A
(es)
|
2002-12-02 |
2005-10-19 |
Abgenix Inc |
Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
PL215171B1
(pl)
|
2002-12-24 |
2013-10-31 |
Rinat Neuroscience Corp |
Przeciwcialo przeciw czynnikowi wzrostu nerwów (NGF) lub jego fragment, kompozycja farmaceutyczna, zestaw, sposób wytwarzania przeciwciala lub jego fragmentu, zastosowanie skutecznej ilosci antagonistycznego przeciwciala anty-NGF lub jego fragmentu, zastosowanie antagonistycznego przeciwciala anty-NGF lub jego fragmentu, izolowany polinukleotyd zawierajacy sekwencje nukleotydowa kodujaca przeciwcialo lub jego fragment, wektor oraz komórka gospodarza zawierajaca polinukleotyd
|
CA2518843A1
(en)
|
2003-03-14 |
2004-09-30 |
Merck & Co., Inc. |
Aryl spirohydantoin cgrp receptor antagonists
|
EP1606264B1
(en)
|
2003-03-14 |
2012-05-02 |
Merck Sharp & Dohme Corp. |
Monocyclic anilide spirohydantoin cgrp receptor antagonists
|
ATE535514T1
(de)
|
2003-03-14 |
2011-12-15 |
Merck Sharp & Dohme |
Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
|
AU2004226018B2
(en)
|
2003-03-14 |
2009-08-27 |
Merck Sharp & Dohme Corp. |
Benzodiazepine spirohydantoin CGRP receptor antagonists
|
DE602004013563D1
(de)
|
2003-03-14 |
2008-06-19 |
Merck & Co Inc |
Rantagonisten
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
ATE466860T1
(de)
|
2003-04-15 |
2010-05-15 |
Merck Sharp & Dohme |
Cgrp-rezeptorantagonisten
|
WO2004097421A2
(en)
|
2003-04-29 |
2004-11-11 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
|
US20060173046A1
(en)
|
2003-07-15 |
2006-08-03 |
Bell Ian M |
Hydroxypyridine cgrp receptor antagonists
|
US20080070239A1
(en)
|
2003-10-29 |
2008-03-20 |
University Of Rochester |
Detection of neureopeptides associated with pelvic pain disorders and uses thereof
|
DE102004015723A1
(de)
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE102004018794A1
(de)
|
2004-04-15 |
2005-10-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7279471B2
(en)
|
2004-04-15 |
2007-10-09 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
CA2563687A1
(en)
|
2004-04-20 |
2005-11-03 |
Boehringer Ingelheim International Gmbh |
Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
|
DE102004027912A1
(de)
|
2004-06-09 |
2005-12-29 |
Grünenthal GmbH |
Substituierte Cyclopenten-Verbindungen
|
US7384930B2
(en)
|
2004-11-03 |
2008-06-10 |
Bristol-Myers Squibb Company |
Constrained compounds as CGRP-receptor antagonists
|
TWI432196B
(zh)
|
2005-01-18 |
2014-04-01 |
Euro Celtique Sa |
內臟痛的治療
|
EP1770091A1
(de)
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
WO2007025212A2
(en)
|
2005-08-25 |
2007-03-01 |
Wex Pharmaceuticals, Inc. |
Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
|
EP2056800B1
(en)
|
2005-08-26 |
2015-12-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Therapy procedure for drug delivery for trigeminal pain
|
CA2623648C
(en)
|
2005-09-21 |
2018-05-22 |
The Regents Of The University Of California |
Systems, compositions, and methods for local imaging and treatment of pain
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
EP3069731A1
(en)
*
|
2005-11-14 |
2016-09-21 |
Labrys Biologics Inc. |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
DE602006019304D1
(de)
|
2005-11-18 |
2011-02-10 |
Merck Sharp & Dohme |
Spirohydantoin-aryl-cgrp-rezeptorantagonisten
|
WO2007076336A1
(en)
*
|
2005-12-22 |
2007-07-05 |
Eli Lilly And Company |
Treatment of migraine with anti-cgrp antibodies
|
CN101516875A
(zh)
|
2006-07-21 |
2009-08-26 |
沃泰克斯药物股份有限公司 |
Cgrp受体拮抗剂
|
US8945505B2
(en)
|
2007-02-02 |
2015-02-03 |
Panaphix, Inc. |
Use of arsenic compounds for treatment of pain and inflammation
|
MX2010004488A
(es)
|
2007-10-23 |
2010-06-17 |
Allergan Inc |
Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
|
JP5745861B2
(ja)
|
2008-03-04 |
2015-07-08 |
ファイザー・リミテッドPfizer Limited |
炎症性疼痛を治療する方法
|
US8293239B2
(en)
|
2008-03-04 |
2012-10-23 |
Pfizer Limited |
Methods of treating chronic pain
|
EP2278939B1
(en)
|
2008-04-25 |
2021-04-14 |
Endologix LLC |
Stent graft delivery system
|
WO2010006168A2
(en)
|
2008-07-09 |
2010-01-14 |
University Of Rochester |
Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
BR112012004464B8
(pt)
|
2009-08-28 |
2021-05-25 |
Labrys Biologics Inc |
uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
|
JO3330B1
(ar)
|
2010-06-10 |
2019-03-13 |
Lilly Co Eli |
الأجسام المضادة cgrp
|
US8669368B2
(en)
|
2010-10-12 |
2014-03-11 |
Bristol-Myers Squibb Company |
Process for the preparation of cycloheptapyridine CGRP receptor antagonists
|
CA3048709A1
(en)
|
2011-05-20 |
2012-11-29 |
Alderbio Holdings Llc |
Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
CN103827290A
(zh)
*
|
2011-05-20 |
2014-05-28 |
奥尔德生物控股有限责任公司 |
多亚基蛋白质例如抗体在转化的微生物例如巴斯德毕赤酵母中的高纯度产生
|
HUE055505T2
(hu)
|
2011-05-20 |
2021-11-29 |
H Lundbeck As |
Anti-CGRP készítmények és alkalmazásuk
|
SG194974A1
(en)
|
2011-05-20 |
2013-12-30 |
Alderbio Holdings Llc |
Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
|
JP6138788B2
(ja)
|
2011-08-19 |
2017-05-31 |
アルダーバイオ・ホールディングズ・エルエルシー |
形質転換した微生物、例えばピキア・パストリス中で抗体などのマルチサブユニットタンパク質を高濃度かつ高純度で生産するための多コピー法
|
SG11201403769YA
(en)
|
2012-01-10 |
2014-07-30 |
Noxxon Pharma Ag |
Nucleic acids specifically binding cgrp
|
US8722060B2
(en)
|
2012-05-23 |
2014-05-13 |
William J. Binder |
Method of treating vertigo
|
US10249132B2
(en)
|
2012-10-29 |
2019-04-02 |
Netent Product Services Ltd. |
Architecture for multi-player, multi-game, multi-table, multi-operator and multi-jurisdiction live casino gaming
|
AU2014232813B2
(en)
|
2013-03-15 |
2017-12-07 |
H. Lundbeck A/S. |
Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
|
CA2907570A1
(en)
|
2013-03-15 |
2014-09-18 |
Alder Biopharmaceuticals, Inc. |
Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
|
KR102476907B1
(ko)
|
2013-07-03 |
2022-12-13 |
하. 룬드벡 아크티에셀스카브 |
항-cgrp 항체를 사용하는 글루코오스 대사의 조절
|
FI3119431T3
(fi)
|
2014-03-21 |
2024-03-20 |
Teva Pharmaceuticals Int Gmbh |
Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
AR101875A1
(es)
|
2014-09-15 |
2017-01-18 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
CA2999809A1
(en)
|
2015-09-24 |
2017-03-30 |
Teva Pharmaceuticals International Gmbh |
Preventing, treating, and reducing (persistent) post-traumatic headache
|
EP3515488A1
(en)
|
2016-09-23 |
2019-07-31 |
Teva Pharmaceuticals International GmbH |
Treating cluster headache
|
CN109952314A
(zh)
|
2016-09-23 |
2019-06-28 |
泰瓦制药国际有限公司 |
治疗难治性偏头痛
|
EP3840836A1
(en)
|
2018-08-22 |
2021-06-30 |
Eli Lilly and Company |
Anti-cgrp antibodies for treatment-resistant patients
|